Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is ...

A new collaboration in the US between the Patient Advocate Foundation's (PAF) Patient Insight Institute, Gilead Sciences and ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Salesforce's outlook fell short of analysts’ expectations, sending shares lower in extended trading Wednesday.

Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...

Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...

Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...